A citation-based method for searching scientific literature

Sebastian Raimundo, Claudia Toscano, Kathrin Klein, Joachim Fischer, Ernst-Ulrich Griese, Michel Eichelbaum, Matthias Schwab, Ulrich M Zanger. Clin Pharmacol Ther 2004
Times Cited: 140

List of co-cited articles
1585 articles co-cited >1

Times Cited
  Times     Co-cited

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Ulrich M Zanger, Sebastian Raimundo, Michel Eichelbaum. Naunyn Schmiedebergs Arch Pharmacol 2004

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Claudia Toscano, Kathrin Klein, Julia Blievernicht, Elke Schaeffeler, Tanja Saussele, Sebastian Raimundo, Michel Eichelbaum, Matthias Schwab, Ulrich M Zanger. Pharmacogenet Genomics 2006

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
S Raimundo, J Fischer, M Eichelbaum, E U Griese, M Schwab, U M Zanger. Pharmacogenetics 2000

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
E U Griese, U M Zanger, U Brudermanns, A Gaedigk, G Mikus, K Mörike, T Stüven, M Eichelbaum. Pharmacogenetics 1998

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.
D Marez, M Legrand, N Sabbagh, J M Lo Guidice, C Spire, J J Lafitte, U A Meyer, F Broly. Pharmacogenetics 1997

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
U M Zanger, J Fischer, S Raimundo, T Stüven, B O Evert, M Schwab, M Eichelbaum. Pharmacogenetics 2001

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
I Johansson, E Lundqvist, L Bertilsson, M L Dahl, F Sjöqvist, M Ingelman-Sundberg. Proc Natl Acad Sci U S A 1993

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.
Johanna Sistonen, Antti Sajantila, Oscar Lao, Jukka Corander, Guido Barbujani, Silvia Fuselli. Pharmacogenet Genomics 2007

Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Kanako Sakuyama, Takamitsu Sasaki, Shuta Ujiie, Kanako Obata, Michinao Mizugaki, Masaaki Ishikawa, Masahiro Hiratsuka. Drug Metab Dispos 2008

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Andrea Gaedigk, L DiAnne Bradford, Kenda A Marcucci, J Steven Leeder. Clin Pharmacol Ther 2002

Polymorphic hydroxylation of Debrisoquine in man.
A Mahgoub, J R Idle, L G Dring, R Lancaster, R L Smith. Lancet 1977

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Silvana Borges, Zeruesenay Desta, Lang Li, Todd C Skaar, Bryan A Ward, Anne Nguyen, Yan Jin, Anna Maria Storniolo, D Michele Nikoloff, Lin Wu,[...]. Clin Pharmacol Ther 2006

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
M L Dahl, I Johansson, L Bertilsson, M Ingelman-Sundberg, F Sjöqvist. J Pharmacol Exp Ther 1995

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
M Oscarson, M Hidestrand, I Johansson, M Ingelman-Sundberg. Mol Pharmacol 1997

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Matthew P Goetz, James M Rae, Vera J Suman, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, David A Flockhart,[...]. J Clin Oncol 2005

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Matthew P Goetz, Stacey K Knox, Vera J Suman, James M Rae, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle,[...]. Breast Cancer Res Treat 2007

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Werner Steimer, Konstanze Zöpf, Silvia von Amelunxen, Herbert Pfeiffer, Julia Bachofer, Johannes Popp, Barbara Messner, Werner Kissling, Stefan Leucht. Clin Chem 2004

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Magnus Ingelman-Sundberg, Sarah C Sim, Alvin Gomez, Cristina Rodriguez-Antona. Pharmacol Ther 2007

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
J Kirchheiner, K Nickchen, M Bauer, M-L Wong, J Licinio, I Roots, J Brockmöller. Mol Psychiatry 2004

CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism.
Andrea Gaedigk, Darren L Ryder, L DiAnne Bradford, J Steven Leeder. Clin Chem 2003

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhart. J Natl Cancer Inst 2003

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Werner Schroth, Lydia Antoniadou, Peter Fritz, Matthias Schwab, Thomas Muerdter, Ulrich M Zanger, Wolfgang Simon, Michel Eichelbaum, Hiltrud Brauch. J Clin Oncol 2007

Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.
A Gaedigk, A Bhathena, L Ndjountché, R E Pearce, S M Abdel-Rahman, S W Alander, L DiAnne Bradford, P K Rogan, J Steven Leeder. Pharmacogenomics J 2005

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, M Ingelman-Sundberg. J Pharmacol Exp Ther 1996

Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
A Wennerholm, I Johansson, M Hidestrand, L Bertilsson, L L Gustafsson, M Ingelman-Sundberg. Pharmacogenetics 2001

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, P B Watkins, A Daly, S A Wrighton, S D Hall,[...]. Nat Genet 2001

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
A C Gough, J S Miles, N K Spurr, J E Moss, A Gaedigk, M Eichelbaum, C R Wolf. Nature 1990

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
R Tyndale, T Aoyama, F Broly, T Matsunaga, T Inaba, W Kalow, H V Gelboin, U A Meyer, F J Gonzalez. Pharmacogenetics 1991

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Werner Steimer, Konstanze Zöpf, Silvia von Amelunxen, Herbert Pfeiffer, Julia Bachofer, Johannes Popp, Barbara Messner, Werner Kissling, Stefan Leucht. Clin Chem 2005

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin, Zeruesenay Desta, Vered Stearns, Bryan Ward, Herbert Ho, Kyung-Hoon Lee, Todd Skaar, Anna Maria Storniolo, Lang Li, Adjei Araba,[...]. J Natl Cancer Inst 2005

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sarah C Sim, Carl Risinger, Marja-Liisa Dahl, Eleni Aklillu, Magnus Christensen, Leif Bertilsson, Magnus Ingelman-Sundberg. Clin Pharmacol Ther 2006

CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Andrea Gaedigk, L Dianne Bradford, Sarah W Alander, J Steven Leeder. Drug Metab Dispos 2006

The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Agneta Wennerholm, Collet Dandara, Jane Sayi, Jan-Olov Svensson, Yakoub Aden Abdi, Magnus Ingelman-Sundberg, Leif Bertilsson, Julia Hasler, Lars L Gustafsson. Clin Pharmacol Ther 2002

Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects.
Andrea Gaedigk, Liliane Ndjountché, J Steven Leeder, L Dianne Bradford. Clin Pharmacol Ther 2005

Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.
David R Nelson, Darryl C Zeldin, Susan M G Hoffman, Lois J Maltais, Hester M Wain, Daniel W Nebert. Pharmacogenetics 2004

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.
A Gaedigk, L Ndjountché, K Divakaran, L Dianne Bradford, I Zineh, T F Oberlander, D C Brousseau, D G McCarver, J A Johnson, S W Alander,[...]. Clin Pharmacol Ther 2007

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
K Abduljalil, D Frank, A Gaedigk, T Klaassen, D Tomalik-Scharte, A Jetter, U Jaehde, J Kirchheiner, U Fuhr. Clin Pharmacol Ther 2010

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
J K Hicks, J J Swen, C F Thorn, K Sangkuhl, E D Kharasch, V L Ellingrod, T C Skaar, D J Müller, A Gaedigk, J C Stingl. Clin Pharmacol Ther 2013

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.